Management of Overweight Patients with Premature Ventricular Contractions

Assessment and Treatment of PVCs

The American College of Cardiology notes that PVCs are common cardiac arrhythmias that increase in frequency with age and may be present in about 50% of all people with or without heart disease 1
The American College of Cardiology recommends evaluating PVC burden, as frequent PVCs (generally >15% of total beats) may produce a reversible form of left ventricular dysfunction 2
The American College of Cardiology suggests assessing for symptoms and determining if PVCs are associated with declining ventricular function, which would require more aggressive treatment 2
For symptomatic PVCs or those associated with declining ventricular function, the American College of Cardiology recommends pharmacological treatment with beta blockers or amiodarone to reduce arrhythmias and improve symptoms and LV function 2
The American College of Cardiology states that for patients with frequent PVCs (>15% of beats) where medications are ineffective, not tolerated, or not preferred, catheter ablation is useful 2

The European Heart Journal recommends implementing a comprehensive lifestyle intervention including caloric restriction and increased physical activity for at least 6-12 months 3
The European Heart Journal suggests targeting a healthy weight with BMI of 18.5-25 kg/m², with initial goal of 5-10% weight loss 4, 3
The European Heart Journal recommends a Mediterranean or similar diet with limited caloric intake and regular physical activity 4
Regular physical activity reduces cardiovascular risk with an inverse relationship between moderate-to-vigorous physical activity and cardiovascular mortality, according to the European Heart Journal 4
The American Heart Association, as published in Circulation, recommends incorporating a structured exercise program with at least 30 minutes of moderate-intensity activity on most days of the week 5, 6

The European Heart Journal suggests considering pharmacological treatment with GLP-1 receptor agonists if weight targets are not reached with lifestyle modifications alone 4
The European Heart Journal recommends that for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities, weight loss medications can be considered as an adjunct to lifestyle changes 7, 3
The SELECT trial, as published in the European Heart Journal, showed significant reduction in cardiovascular events in patients with pre-existing cardiovascular disease who were overweight/obese but without diabetes when treated with semaglutide 4
The SURMOUNT trials, as published in the European Heart Journal, demonstrated significant weight loss benefits in obese adults without diabetes with tirzepatide 4

The Clinical Gastroenterology and Hepatology journal recommends implementing a regular follow-up schedule to monitor both weight management progress and cardiac status 7
The Clinical Gastroenterology and Hepatology journal suggests assessing efficacy of weight management interventions at least monthly for the first 3 months, then every 3 months 7
The American College of Cardiology notes that if PVC burden remains high despite weight loss, reassessing the need for antiarrhythmic therapy or ablation is necessary 2

The American College of Cardiology warns against using class I sodium channel-blocking antiarrhythmic medications in post-MI patients or those with reduced LVEF as they increase mortality risk 1
The Clinical Gastroenterology and Hepatology journal notes that some weight loss medications may have cardiovascular effects that could impact arrhythmia management 7
The American College of Cardiology states that it may be difficult to determine whether PVCs caused LV dysfunction or whether progressive LV dysfunction caused frequent PVCs 2
The Clinical Gastroenterology and Hepatology journal recommends viewing weight loss interventions as tools that require sustained lifestyle changes for ultimate success 7